Literature DB >> 14757166

Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors.

François Mailliet1, Valérie Audinot, Benoit Malpaux, Anne Bonnaud, Philippe Delagrange, Martine Migaud, Perry Barrett, Marie-Claude Viaud-Massuard, Daniel Lesieur, François Lefoulon, Pierre Renard, Jean A Boutin.   

Abstract

The variations of the pharmacological properties of melatonin receptors between different mammalian species in transfected cell lines have been poorly investigated. In the present study, melatonin analogues have been used to characterize the pharmacology of the recombinant ovine melatonin receptor (oMT1) expressed in CHO cell lines and the native oMT1 from the pars tuberalis (PT). Studies with selective ligands on native and transfected oMT1 showed similar properties for binding affinities [r2(PT/CHO) = 0.85]. The affinities and the functional activities of these ligands were compared with the human receptors (hMT1 or hMT2) expressed in CHO cells as well. The oMT1 and hMT1 receptors had similar pharmacological profiles (r2=0.82). Nevertheless, some of the selective compounds at the human receptor presented a reduced affinity at the ovine receptor. Furthermore, some compounds showed marked different functional activities at oMT1 vs. hMT1 receptors. Our findings demonstrated differences in the pharmacological properties of melatonin receptors in ovine and human species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14757166     DOI: 10.1016/j.bcp.2003.09.037

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

Review 1.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

2.  Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state.

Authors:  Céline Legros; Séverine Devavry; Sarah Caignard; Clémence Tessier; Philippe Delagrange; Christine Ouvry; Jean A Boutin; Olivier Nosjean
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease.

Authors:  Gianluca Tosini; Sharon Owino; Jean-Luc Guillaume; Ralf Jockers
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

4.  Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase.

Authors:  Gilles Ferry; Caroline Ubeaud; Pierre-Hervé Lambert; Sophie Bertin; Francis Cogé; Pascale Chomarat; Philippe Delagrange; Bernard Serkiz; Jean-Paul Bouchet; Roger J W Truscott; Jean A Boutin
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

5.  Alternative Ligands at Melatonin Receptors.

Authors:  Céline Legros; Said Yous; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

6.  Why Are We Still Cloning Melatonin Receptors? A Commentary.

Authors:  Célia Gautier; Isabelle Theret; Giulia Lizzo; Gilles Ferry; Sophie-Pénélope Guénin; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

7.  The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor.

Authors:  F Cogé; S P Guenin; I Fery; M Migaud; S Devavry; C Slugocki; C Legros; C Ouvry; W Cohen; N Renault; O Nosjean; B Malpaux; P Delagrange; J A Boutin
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

8.  Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes.

Authors:  Christel Logez; Sylvie Berger; Céline Legros; Jean-Louis Banères; William Cohen; Philippe Delagrange; Olivier Nosjean; Jean A Boutin; Gilles Ferry; Frédéric Simonin; Renaud Wagner
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

9.  Expression of the MT1 melatonin receptor in ovarian cancer cells.

Authors:  Karolina Jablonska; Bartosz Pula; Agata Zemla; Christopher Kobierzycki; Witold Kedzia; Ewa Nowak-Markwitz; Marek Spaczynski; Maciej Zabel; Marzenna Podhorska-Okolow; Piotr Dziegiel
Journal:  Int J Mol Sci       Date:  2014-12-12       Impact factor: 5.923

10.  New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors.

Authors:  Céline Legros; Ulrich Matthey; Teresa Grelak; Sandrine Pedragona-Moreau; Werner Hassler; Saïd Yous; Emmanuel Thomas; Franck Suzenet; Benoît Folleas; François Lefoulon; Pascal Berthelot; Daniel-Henri Caignard; Gérald Guillaumet; Philippe Delagrange; Jean-Louis Brayer; Olivier Nosjean; Jean A Boutin
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.